奥克巴胺 | 104-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 奥克巴胺
• 中文别名: 羟苯乙醇胺；章胺；1-(4-羟基苯基)-2-氨基乙醇；奥克帕胺；去甲对羟印鱼章胺；章鱼胺;；苯乙醇胺；章鱼胺；酚乙醇胺；真蛸胺
• 英文名称: octopamine
• 英文别名: 2-amino-1-(4-hydroxy-phenyl)-ethanol；p-octopamine；4-(2-amino-1-hydroxyethyl)phenol
• CAS: 104-14-3
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: QHGUCRYDKWKLMG-UHFFFAOYSA-N

物化性质

• 熔点：
  157-158 °C
• 沸点：
  276.1°C (rough estimate)
• 密度：
  1.1577 (rough estimate)
• 溶解度：
  Water (Easy)
• 稳定性/保质期：
  可燃；燃烧会产生有毒的氮氧化物烟雾。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1(b)
• 危险品运输编号：
  3249
• 海关编码：
  2922509090
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 储存条件：
  库房应保持通风、低温和干燥的环境。

制备方法与用途

类别：有毒物品
毒性分级：高毒
急性毒性：腹腔-小鼠LD50: 600 毫克/公斤；静脉-小鼠LD50: 75 毫克/公斤
可燃性危险特性：可燃；燃烧时产生有毒氮氧化物烟雾
储运特性：库房应通风、低温且干燥
灭火剂：干粉、泡沫、砂土、二氧化碳或雾状水

反应信息

• 作为反应物：
  描述：

  奥克巴胺 在 palladium on activated charcoal 、 溶剂黄146 作用下， 生成 对羟基苯乙胺
  参考文献：
  名称：

  Fodor; Kovacs, Pharmazeutische Zentralhalle, 1951, vol. 90, p. 291,294

  摘要：

  DOI：
• 作为产物：
  描述：

  酪胺盐酸盐 在 dopamine β-hydroxylase N-乙基马来酰亚胺 、 acetate buffer 、 rat plasma 、 fumaric acid disodium salt 、 copper(II) sulfate 、 维生素 C 作用下， 以 水 为溶剂， 生成 奥克巴胺
  参考文献：
  名称：

  Fluorimetric assay for dopamine .BETA.-hydroxylase in rat plasma.

  摘要：

  本研究介绍了一种检测大鼠血浆中多巴胺β-羟化酶的灵敏荧光法。在 Dowex 50W-X4 色谱柱上用酶法分离底物酪胺生成的多巴胺，并用高碘酸盐将其氧化为对羟基苯甲醛，然后用 2，2'-二硫代双（1-氨基萘）选择性测定芳香醛的荧光法对其进行定量。该方法操作简便，精确度高，适用于同时检测多种样品。

  DOI：

  10.1248/cpb.28.3385
• 作为试剂：
  描述：

  聚合甲醛 、 正丁醛 在 奥克巴胺 作用下， 以 水 为溶剂， 以14.15%的产率得到2-乙基丙烯醛
  参考文献：
  名称：

  活细菌中代谢丁醛的生物相容性α-甲基化

  摘要：

  将新的非生物化学引入活细胞是化学生物技术领域的一项巨大挑战。在这里，我们表明磷酸盐和/或生物胺在生物相容性反应条件下介导丁醛的非酶促α-甲基化，并且可以与大肠杆菌中D-葡萄糖的丁醛生物合成相结合。

  DOI：

  10.1002/anie.202306347

文献信息

• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011076678A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式I的化合物，其中R是氢或较低的烷基；R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基基团可选择地被较低的烷基，羟基，卤素或-(CH2)p-芳基取代；n为0、1或2；o为0或1；p为0、1或2；R2为CF3，环烷基，可选择地被较低的烷氧基或卤素取代，或为茚-2-基，或为杂环烷基，可选择地被杂芳基取代，或为芳基或杂芳基，其中芳香环可选择地被来自较低的烷基，卤素，杂芳基，羟基，CF3，OCF3，OCH2CF3，OCH2-环烷基，OCH2C(CH2OH)(CH2C1)(CH3)，S-较低的烷基，较低的烷氧基，CH2-较低的烷氧基，较低的炔基或氰基，或-C(O)-苯基，-O-苯基，-O-CH2-苯基，苯基或-CH2-苯基选择的一个或两个取代基取代，其中苯环可选择地被卤素，-C(O)-较低的烷基，-C(O)OH或-C(O)O-较低的烷基取代，或芳香环可选择地被杂环烷基，OCH2-氧杂环戊烷-3-基或O-四氢吡喃-4-基，可选择地被较低的烷基取代；X为键，-NR'-，-CH2NH-，-CHR''-，-(CHR'')q-O-，-O-(CHR'')q-或-(CH2)2-；Y为键或-CH2-；R'为氢或较低的烷基，R''为氢，较低的烷基，CF3，较低的烷氧基，q为0、1、2或3；或其药学上适宜的酸盐。现已发现，该式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，躁郁症，注意力缺陷多动障碍（ADHD），与压力有关的疾病，如精神分裂症，帕金森病等神经疾病，阿尔茨海默病等神经退行性疾病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收异常，体温稳态异常，睡眠和昼夜节律异常，以及心血管疾病。
• Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
  申请人：Dow AgroSciences LLC

  公开号：US20180279612A1

  公开（公告）日：2018-10-04

  This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

  这份披露涉及具有对节肢动物门、软体动物门和线虫门害虫具有杀虫效用的分子领域，用于生产此类分子的过程，用于此类过程的中间体，含有此类分子的杀虫组合物，以及使用此类杀虫组合物对抗此类害虫的过程。这些杀虫组合物可以用作螨虫剂、杀虫剂、螨虫剂、软体动物杀虫剂和线虫杀虫剂。本文件披露了具有以下式（“式一”）的分子。
• [EN] PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168260A1

  公开（公告）日：2012-12-13

  The invention relates to compounds of formula wherein R1 is hydrogen or phenyl, optionally substitutes by halogen, CN or lower alkoxy or lower alkoxy substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen or lower alkyl or is phenyl optionally substituted by one or more substituents, selected from halogen, cyano or lower alkoxy substituted by halogen, or is pyridinyl, optionally substituted by halogen or lower alkyl substituted by halogen, or is pyrimidinyl, optionally substituted by lower alkyl substituted by halogen, or is pyrazinyl, optionally substituted by halogen, cyano or lower alkyl substituted by halogen; R4 is hydrogen, lower alkyl or phenyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas IA and IB have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式中的化合物，其中R1是氢或苯基，可选择由卤素、CN或较低的烷氧基或由卤素取代的较低的烷氧基取代；R2是氢或较低的烷基；R3是氢或较低的烷基或是苯基，可选择由卤素、氰基或由卤素取代的较低的烷氧基取代，或是吡啶基，可选择由卤素或由卤素取代的较低的烷基取代，或是嘧啶基，可选择由较低的烷基取代的较低的烷基取代，或是吡嗪基，可选择由卤素、氰基或由卤素取代的较低的烷基取代；R4是氢、较低的烷基或苯基；Z是键，-CH2-或-O-；或其药学上适宜的酸盐。现已发现，IA和IB式的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的疾病、如精神分裂症等精神疾病、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• Iron-Catalyzed Aminohydroxylation of Olefins
  作者：Kevin S. Williamson、Tehshik P. Yoon

  DOI：10.1021/ja1013536

  日期：2010.4.7

  broad range of olefins in the presence of iron salts to afford 1,3-oxazolidines. This process provides access to 1,2-aminoalcohols with the opposite sense of regioselectivity produced from the copper-catalyzed oxyamination previously reported by our laboratories. Thus, either regioisomeric form of 1,2-aminoalcohols can easily be obtained from the reaction of oxaziridines with olefins, and the sense

  我们发现 N-磺酰基恶氮丙啶在铁盐存在下与范围广泛的烯烃反应得到 1,3-恶唑烷。该过程提供了获得 1,2-氨基醇的途径，其具有与我们实验室先前报道的铜催化氧化胺化产生的区域选择性相反的意义。Thus, either regioisomeric form of 1,2-aminoalcohols can easily be obtained from the reaction of oxaziridines with olefins, and the sense of regioselectivity can be controlled by the appropriate choice of inexpensive, nontoxic, first-row transition-metal catalyst.
• Benzyloxy derivatives as MAOB inhibitors
  申请人：Jolidon Synese

  公开号：US20050288367A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.

  这项发明涉及以下公式的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、n、m和o如规范中所定义。这些化合物是选择性单胺氧化酶β抑制剂，对治疗和预防阿尔茨海默病和老年性痴呆症以及其他中枢神经系统疾病有用。该发明还涉及制备这类化合物的方法和含有它们的药物组合物。